Antares Pharma to Host First Quarter 2009 Earnings Call

EWING, N.J.--(Business Wire)--
Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will release its
first quarter 2009 financial results before the market opens on Wednesday, May
13, 2009, and host a conference call shortly thereafter at 8:30 AM (Eastern
Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief
Executive Officer, and Robert F. Apple, Chief Financial Officer, will host the
call.

Interested parties may participate in the conference call by dialing
1-877-941-2930 (US), or 1-480-629-9726 (International), 5-10 minutes prior to
the start of the call. A replay of the conference call will be available
approximately 2 hours after the call`s conclusion through 12:00 PM Eastern Time
on May 27, by dialing 800-406-7325 (US), or 303-590-3030 (International), and
entering reservation #4066167. An audio web cast and archive of the conference
call will also be available under the investor relations section of the Antares
website at www.antarespharma.com.

About Antares Pharma (www.antarespharma.com)

Antares Pharma is a product development company committed to improving
pharmaceuticals through its patented drug delivery systems. Antares has multiple
development partnerships with leading pharmaceutical companies. The Company`s
products are designed to improve safety and efficacy profiles by minimizing
dosing and reducing side effects while enabling improved patient compliance. The
Company`s lead product candidate, Anturol, an oxybutynin ATD gel for the
treatment of OAB (overactive bladder), is currently under evaluation in a
pivotal Phase 3 trial. Antares has three validated drug delivery systems: the
ATDTM Advanced Transdermal Gel Delivery system; subcutaneous injection
technology platforms, including VibexTM disposable pressure-assisted auto
injectors, ValeoTM/Vision reusable needle-free injectors, and disposable
multi-use pen injectors; and Easy TecTM oral disintegrating tablets (ODT). Two
of the systems have generated FDA-approved products. Antares Pharma has
corporate headquarters in Ewing, New Jersey, with subsidiaries performing
research, development, manufacturing and product commercialization activities in
Minneapolis, Minnesota and Basel, Switzerland.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include statements related to the Company`s
future financial performance, and other statements which are other than
statements of historical facts. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "expects," "intends,"
"plans," anticipates," "believes," "estimates," "predicts," "projects,"
"potential," "continue," and other similar terminology or the negative of these
terms, but their absence does not mean that a particular statement is not
forward-looking. Such forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the forward-looking
statements. These risks and uncertainties include, among others: that the
Company may experience difficulties or delays in the initiation, progress, or
completion of its clinical trials, including the phase 3 trial of Anturol,
whether caused by competition, adverse events, investigative site initiation
rates, patient enrollment rates, regulatory issues, or other factors; that
clinical trials may not demonstrate that Anturol is both safe and effective for
the treatment of patients with overactive bladder syndrome; that the safety
and/or efficacy results of the phase 3 trial of Anturol may not support an
application for marketing approval in the United States or any other country;
that an application for marketing approval may not be accepted by the FDA or any
other regulatory authority; and that the Company may lack the financial
resources and access to capital to fund future clinical trials. Additional
information concerning these and other factors that may cause actual results to
differ materially from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2008, and in the Company's other periodic
reports and filings with the Securities and Exchange Commission. The Company
cautions investors not to place undue reliance on the forward-looking statements
contained in this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of this press
release, except as required by law.

Antares Pharma
Robert F. Apple, Chief Financial Officer, 609-359-3020
or
In-Site Communications, Inc.
Lisa Wilson, President, 917-543-9932
lwilson@insitecony.com

Copyright Business Wire 2009